Abstract
Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Current Proteomics
Title: Toxicoproteomics: Applications in Drug Development
Volume: 2 Issue: 2
Author(s): N. Gupta, A. Law, R. Poddar, M. Louie, A. Ray and D. N. Chakravarti
Affiliation:
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Abstract: Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Export Options
About this article
Cite this article as:
Gupta N., Law A., Poddar R., Louie M., Ray A. and Chakravarti N. D., Toxicoproteomics: Applications in Drug Development, Current Proteomics 2005; 2 (2) . https://dx.doi.org/10.2174/1570164054494181
DOI https://dx.doi.org/10.2174/1570164054494181 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine The Effects of the “XGTQ” Medicine in Treating Cirrhosis in Wistar Rats
Current Traditional Medicine Alpha Fetoprotein is More than a Hepatocellular Cancer Biomarker: From Spontaneous Immune Response in Cancer Patients to the Development of an AFP-Based Cancer Vaccine
Current Molecular Medicine Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology EGFR Inhibitors and Radiation in HNSCC
Current Cancer Therapy Reviews The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry PI-3-Kinase Inhibitors in Colorectal Cancer
Current Cancer Drug Targets Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Therapeutic Antibodies
Current Molecular Medicine Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters